Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$76.13 USD

76.13
2,260,926

+2.01 (2.71%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong

Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.

    Arpita Dutt headshot

    Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline

    Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?

      Arpita Dutt headshot

      Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug

      Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.

        Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed

        Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.

          Incyte & Lilly's Olumiant Gets Marketing Approval in Japan

          Incyte Corporation (INCY) and partner Eli Lilly and Company (LLY) announced that arthritis drug Olumiant got approval in Japan.

            Aduro Starts Phase II Combo Study with CRS-207 & Keytruda

            Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).

              Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

              Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                Arpita Dutt headshot

                Better Days Ahead for the Pharma Sector?

                Sales, R&D, strong results, and a higher number of FDA approvals.

                  Eric Dutram headshot

                  Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger

                  This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in this area, check it out for more info on this interesting biotech segment!

                    Incyte (INCY) Up 3.4% Since Earnings Report: Can It Continue?

                    Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                      Incyte Provides Updated Data on Cancer Combination Therapies

                      Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.

                        Incyte Announces Data on Enzyme Inhibitor with Keytruda

                        Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.

                          Company News for May 19, 2017

                          Companies in the News are: LB,P,INCY,MRK,SHPG

                            Incyte (INCY) Announces Positive Data on Enzyme Inhibitor

                            Incyte Corporation (INCY) recently announced that new data was published from the ongoing trial, ECHO-202 online by the American Society of Clinical Oncology (ASCO).

                              Concert Pharma Falls After Clinical Hold on Hair Loss Drug

                              Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.

                                Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat

                                Incyte's first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations.

                                  5 Toxic Stocks to Dispose of or Play Short for Profit

                                  Just like picking stocks with growth potential, pinpointing toxic stocks and discarding them at the right time is the key to shield your portfolio from big losses or make profits by short selling them.

                                    Should You Get Rid of Incyte Corporation (INCY) Now?

                                    Investors may consider dropping the Zacks Rank #4 Incyte Corporation (INCY) stock, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.

                                      Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down

                                      Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.

                                        Arpita Dutt headshot

                                        Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed

                                        Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.

                                          Tracey Ryniec headshot

                                          Should You Make a Bet on the Healthcare Stocks?

                                          The healthcare industry is much more than Obamacare and drug prices as many companies are using new technologies to create breakthroughs in medicine.

                                            Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals

                                            Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals

                                              Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.

                                              Eli Lilly and Company (LLY) and its partner Incyte Corporation (INCY) recently announced that they have received a Complete Response Letter (CRL) from the FDA regarding the new drug application (NDA) for baricitinib.

                                                5 Toxic Stocks to Shun or Play Short Right Now

                                                Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them.

                                                  Agenus (AGEN) Sharpens Focus on Drug Development Programs

                                                  We issued an updated report on Agenus Inc. (AGEN) on Apr 4.